HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].

AbstractOBJECTIVE:
To study correlations between parameters of lipid metabolism and ECG in patients with schizophrenia in light of therapy with atypical antipsychotics.
MATERIAL AND METHODS:
We examined 42 patients with paranoid schizophrenia. All patients received atypical neuroleptics - seroquel, zyprexa, and rispolept. A group of controls included 25 healthy people.
RESULTS:
There was a significant increase (p=0.0002) in body mass (in average by 1.5 kg) in 88% patients. A significant increase in the concentration of serum triglycerides was identified as well. The concentration of VLDL in the patients with schizophrenia was 2 times higher compared to controls. After treatment, VLDL concentration increased even more considerably An increase in atherogenic index (AI) was up to 3.1 in patients with schizophrenia compared to 2.2 in controls. After treatment, Al increased up to 4 that demonstrated the high risk of development of atherosclerosis. A significant increase in QT interval in the ECG and heart rate (p=0.03) was revealed only in patients receiving rispolept. In patients receiving zyprexa and seroquel only heart rate was increased.
CONCLUSION:
The antipsychotics studied increase the risk of development of cardiovascular pathology.
AuthorsL P Smirnova, D A Parshukova, Yu N Borodyuk, E G Kornetova, G D Tkacheva, A A Seregin, T G Burdovitsina, A V Semke
JournalZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoĭ promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe obshchestvo nevrologov [i] Vserossiĭskoe obshchestvo psikhiatrov (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 115 Issue 3 Pg. 49-53 ( 2015) ISSN: 1997-7298 [Print] Russia (Federation)
PMID26120982 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antipsychotic Agents
  • Dibenzothiazepines
  • Lipoproteins, VLDL
  • Benzodiazepines
  • olanzapine
  • Quetiapine Fumarate
  • Risperidone
Topics
  • Adult
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Atherosclerosis (blood, chemically induced)
  • Benzodiazepines (adverse effects, therapeutic use)
  • Dibenzothiazepines (adverse effects, therapeutic use)
  • Electrocardiography
  • Female
  • Humans
  • Lipid Metabolism (drug effects)
  • Lipoproteins, VLDL (blood)
  • Male
  • Middle Aged
  • Quetiapine Fumarate
  • Risperidone (adverse effects, therapeutic use)
  • Schizophrenia, Paranoid (blood, drug therapy, physiopathology)
  • Weight Gain
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: